Reptilase: Haemocoagulase 1 NIH Unit

Reptilase
Haemocoagulase
1 NIH unit
Troikaa P’cals Ltd, India

Reptilase
• Haemocoagulase is a mixture of purified
enzymes isolated from the venom of South
American viper, called Bothrops atrox. It is
completely free of neurotoxins and other toxic
substances
• A proteolytic enzyme obtained from the
venom of fer-de-lance (Bothrops atrox). It is
used as a plasma clotting agent for fibrinogen
and for the detection of fibrinogen
degradation products
• Haemocoagulase has two different enzymatic
activities, which promote blood coagulation
• One accelerates conversion of prothrombin to
thrombin (thromboplastin like enzymes)
• Other one causes a direct transformation of
fibrinogen to fibrin monomer, which can be
converted by thrombin into fibrin clot (thrombin like
enzymes)
• In-vitro, the thrombin like enzyme coagulates
fibrinogen by gradually splitting off
fibrinopeptide A, in contrast to thrombin,
which removes both fibrinopeptides A and B.
This give rise to des-A-fibrin monomers, which
polymerize end-to-end to form fibrin clot.
• However, unlike thrombin, the thrombin like
activity of Haemocoagulase is not inhibited by
antithrombins such as heparin. In the circulating
blood, the des-Afibrin monomer produced by
Haemocoagulase remains in solution because it
forms a complex with native fibrinogen. These
complexes of high molecular weight accelerate
the platelet aggregation and reduce capillary
permeability at the site of the vascular injury.
• The thromboplastin enzyme activates Factor X,
essentially in the presence of factor III, released
from platelets aggregated at the bleeding site.
The activated Factor Xa then supports thrombin
formation at the site of hemorrhage.
• However, in vitro, thromboplastin like enzymes
can convert prothrombin to thrombin, even in
the absence of Factor III and Factor X.
• Thus Haemocoagulase shortens the bleeding
and clotting time, by promoting coagulation at
bleeding sites and reduces blood loss.
Haemocoagulase in therapeutic doses does
not cause intravascular coagulation, and only
promotes the physiological processes of
hemostasis.
• Following intravenous administration, the
hemostatic effect becomes apparent after 5 to
10 minutes and lasts for 24 hours. After
intramuscular or subcutaneous
administration, the action starts after 20 to 30
minutes and the duration of action is 48 to 60
hours. After local spraying or applying soaked
swab on the bleeding surface, the action
starts within a minute.
• 20 minutes after the injection of 1 unit of this
product, bleeding time for healthy adults is
measured to shorten by 1/2 to 2/3. This
clinical effect will last 2 to 3 days.
• This product only functions on bleeding stop
with no effect on blood thrombin quantity. So
there is no possibility of forming thrombus by
using this product.
• Haemorrhages of diverse aetiology of medical,
surgical,gynaecological and dental origin
• Thrombotic or embolic episodes.
• Adult :1ml by IM/IV/SC
• Children:0.3ml 0.5ml.
• [Forbidden Group]:
1. Thrombus patients or thrombus history
patients although there is no report of
forming thrombus by using this product.
2. Patients allergic to this product or
similar products.
• [Notice]:
1. Pregnant women are not suggested to use this product unless it’s urgent.
2. Dispersed Intra blood vessel Coagulation (DIC) or blood disease patients are not
suggested to use this product.
3. When lack of blood platelet or blood coagulation agent such as thrombin
proenzyme, this product is not a substitute but should be used after blood platelet
or blood coagulation agent is compensated, or new blood is transmitted.
4. When idiopathy fibrinolytic system is sthenic, for example, after endocrine gland
or cancer operation. This product should be used together with fibrinolysin
medicine.
5. Avoid over dosed. Over dosage will decrease the function of bleeding stop.
6. Observe the situation of bleeding and blood coagulation while treating the
patients.
• It’s very seldom to have side effect.
Occasionally there is allergy. Just treat as
ordinary allergy by using antihistaminic or
similar.
Clinical trials
Competitors
Targeted Dr.
• Physicians

Reptilase: Haemocoagulase 1 NIH Unit

Uploaded by

Copyright:

Available Formats

Reptilase: Haemocoagulase 1 NIH Unit

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Reptilase: Haemocoagulase 1 NIH Unit

Uploaded by

Copyright:

Available Formats

Reptilase

Troikaa P’cals Ltd, India

You might also like